Stock vs Stock Comparison

Bristol-Myers Squibb Company vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–3.

BMY$54.46
LLY$1064.15

🏆 Tale of the Tape

36
BMYLLY
14.6%Profitability (Net Margin)31.7%
16.0xValuation (P/E)39.2x
13.3%Efficiency (ROIC)30.4%
9/9Health (Piotroski F)7/9
2.3Safety (Altman Z)7.8
-0.2%Growth (Rev YoY)44.7%
0.38Risk (Sharpe 1Y)0.61
3.87xBalance Sheet (D/E)3.24x
8.43%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.402
252-Day Correlation
0.388
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricBMYLLY
Market Cap$116.8B$985.4B
P/E Ratio16.0x39.2x
Forward P/E9.3x24.8x
P/B5.82x31.65x
Dividend Yield4.41%0.63%
Beta0.260.48

Quantitative Metrics

MetricBMYLLY
DCF Fair Value$102.60$296.11
DCF Upside+76.7%-68.2%
Piotroski F9/97/9
Altman Z2.297.84
Beneish M-2.73-1.91
FCF Yield8.43%0.68%
Net Debt/EBITDA2.1x1.1x
ROIC13.3%30.4%
WACC6.9%7.8%
ROIC – WACC6.4pp22.5pp
Gross Margin71.1%83.0%
Net Margin14.6%31.7%
Rev Growth YoY-0.2%44.7%
Sharpe (1Y)0.380.61
Max Drawdown 3Y
FCF Payout Ratio39%90%

BMY Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

BMY found in:

SCHD4.28%
MOAT2.70%
XLV2.26%
VHT2.00%
XPH1.81%
SPYD1.30%
VFVA0.98%
MGV0.61%
VYM0.51%
VTV0.48%
SCHV0.43%
SPYV0.42%
IWD0.33%
VONV0.30%
ESGV0.25%
RSP0.21%
SCHX0.20%
VOO0.20%
SCHB0.19%
VONE0.19%
SPY0.19%
IVV0.19%
VTI0.18%
SPTM0.18%
ITOT0.17%
QUS0.15%
URTH0.15%
SPLG0.15%
ACWI0.12%
VT0.11%
IWF0.09%
VONG0.08%
ONEO0.03%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BMY vs LLY: Head-to-Head Analysis

Bristol-Myers Squibb Company (BMY) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BMY generates a return on invested capital (ROIC) of 13.3% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BMY and LLY is 0.402, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

BMY appears in 33 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BMY or LLY?

Our quantitative analysis compares BMY and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BMY and LLY correlated?

The 252-day correlation between BMY and LLY is 0.402. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.